#pharmaceuticals

#pharmaceuticals

Tariffs on pharmaceuticals could significantly raise medication prices for US patients without exceptions in place.

Trump's proposed tariffs on pharmaceuticals could lead to higher costs and shortages of medications for U.S. patients.

Potential tariffs on pharmaceuticals may significantly impact drug availability and pricing in the U.S.

The US is Germany's largest export market, accounting for about 10.4% of its total exports in 2024.

The US trade surplus with Ireland, particularly in pharmaceuticals, has been a point of contention for the US president.

Eli Lilly's orforglipron shows significant weight loss for Type 2 diabetes patients, potentially rivaling injectable medications.

Lilly's shares surged 15% following promising clinical trial results for orforglipron.

Eli Lilly aims to develop a once-per-year weight-loss shot for easier obesity management.

Hims & Hers has partnered with Novo Nordisk to offer Wegovy, leading to a significant stock surge.

New weight-loss medications are aiming to improve upon existing drugs like Ozempic and Wegovy by offering enhanced benefits and resolving current treatment limitations.

Weight-loss drugs require careful medical supervision due to serious side effects and potential risks.

AstraZeneca invests $2.5 billion in Beijing to bolster research, moving past recent controversies while collaborating with local biotech firms.

Ono Pharma USA is laying off 83 employees, indicating a continuing trend of layoffs in the biotech sector.

Eli Lilly's Zepbound reaches 100,000 direct buyers monthly, showing a shift towards online drug sales despite insurance coverage limitations.

Eli Lilly's new obesity and diabetes drug 'orforglipron' faces challenges due to its complicated name.

Brexit is negatively impacting access to life-saving cancer drugs for UK patients.

Cancer is the second leading cause of death globally, requiring urgent advancements in diagnosis and treatment to keep pace with the rising incidence.

Emerging biopharmaceutical companies are increasingly dominating the oncology clinical trial landscape, reflecting their growing importance in cancer research.

The ongoing demand for GLP-1s has resulted in a significant shortage and legal dispute regarding alternative compounding pharmacies.

FDA allowed compounding pharmacies a grace period to cease production post-drug shortage, but some continue to sell modified tirzepatide products.

AbbVie's fourth-quarter earnings exceeded expectations, driven by strong sales of Skyrizi and Rinvoq.

Pfizer's stock has declined significantly despite strong earnings and a high dividend yield.

The company anticipates revenue growth driven by new drug sales, especially in oncology.

Market uncertainty deters investors from speculative industries; however, many biotech stocks are undervalued and present opportunities.

Viking Therapeutics shows significant stock growth since its IPO and is anticipated to continue this upward trend.

Billionaire Stanley Druckenmiller significantly increased his stake in Teva Pharmaceuticals by 530%, making it the fourth largest holding in his firm.

Tavapadon shows promise for Parkinson's by reducing symptoms more effectively and with fewer side effects than traditional treatments.

The Federal Circuit affirmed Amgen's biosimilar, emphasizing its unique formulation and contrasting it with prior rulings against other manufacturers.

Healthcare providers should embrace the 'Food is Medicine' movement as Americans demand nutrition guidance over pharmaceuticals.

Drug shortages in the UK are at a four-year high, largely attributed to Brexit-related supply chain issues.

A strange healing mushroom becomes a symbol of conflict between altruism and the medical establishment's interests.

Lazarus explores a dystopian future where a miracle drug turns deadly, prompting a desperate search for the antidote.

Lazarus is a new anime by Shinichirō Watanabe that aims to combine excitement with a complex narrative.

The show features a revolutionary painkiller that hides a deadly secret, creating a race against time.

AstraZeneca's annual meeting is overshadowed by investigations and pay protests despite strong financial performance.

AstraZeneca cancelled a £450 million investment in the UK due to financial disagreements with the government.

AstraZeneca's profits surged despite pulling back on investments due to unmet government support.

AstraZeneca aims for $80 billion in revenue by 2030, potentially exceeding $100 billion if growth continues.

Generic pharmaceutical companies can now deduct legal expenses from patent litigation as ordinary business expenses.

The Federal Circuit reversed the invalidation of Novartis' patent for lack of written description, affirming other findings of non-obviousness and enablement.

Mylan's proposed ANDA label is found to likely induce infringement of Janssen's patent on antipsychotic treatments, according to the Federal Circuit.

Ignota Labs leverages AI to revitalize failed drug candidates, increasing efficiency in the drug modification process and reducing costs significantly.

US pharma companies are returning manufacturing to America due to political pressures.

The ad for Hims & Hers promotes weight-loss drugs while minimizing discussions of safety, leading to backlash from lawmakers and health professionals.

Scratching an itch activates the immune response, potentially protecting against infections and revealing a satisfying sensation for humans.